Clinical trial NCT03254810: Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects
Official title: A Phase 1 Randomized Blinded Single Dose Comparison of the Safety and Pharmacokinetics of SYN060 Compared to Adalimumab (Humira®) From North American and European Sources in Healthy Adult Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Arthritis, Rheumatoid
Lead sponsor: Synermore Biologics Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2017-08-21
Enrollment: 94
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a single site, parallel randomized, double blinded comparison of the safety, pharmacokinetics, and immunogenicity of a single 0.57 mg/kg dose of SYN060 to a single 0.57 mg/kg dose of adalimumab (Humira®) reference product from North American and European sources. The study is open to healthy individuals on no medications that might confound the results of this safety study.

Detailed description: This is a single site, parallel randomized, double blinded comparison of the safety, pharmacokinetics, and immunogenicity of a single 0.57 mg/kg dose of SYN060 to a single 0.57 mg/kg dose of adalimumab (Humira®) reference product from North American and European sources. The study is open to healthy individuals on no medications that might confound the results of this safety study.

A total of 90 subjects will be randomized in a 1:1:1 ratio to from a centrally generated randomization schedule to SYN060 or adalimumab of American or European sources resulting in 30 subjects in each group.

Eligibility criteria: Inclusion Criteria:

1. Male or female subjects between 18 and 50 years of age, inclusive
2. Body mass index between 18 and 30 kg/m², inclusive
3. Female subjects physically capable of pregnancy (i.e., not sterilized and still menstruating or within 1 year of the last menses if menopausal) must:

   1. Agree to avoid pregnancy from the Study Day screening visit through six months after receipt of Study Drug.
   2. If in a sexual relationship with a man, use an acceptable method of avoiding pregnancy during this period, still menstruating or within 1 year of the last menses if menopausal) in sexual relationships with men must use an acceptable method of avoiding pregnancy during this period. Acceptable methods of avoiding pregnancy include a sterile sexual partner, sexual abstinence (not engaging in sexual intercourse), hormonal contraceptives (oral, injection, transdermal patch, or implant), vaginal ring or intrauterine device (IUD).
4. Women of childbearing potential must have a negative serum pregnancy test within 24 hours preceding receipt of the dose.
5. Can understand and sign the informed consent document, can communicate with the investigator and provide updated contact information as needed for the duration of the study, has no current plans to move from the study area for the duration of the study, and can understand and comply with the requirements of the protocol.

Exclusion Criteria:

1. Acute illness on Study Day 1
2. Oral temperature ≥37.5°C on Study Day 1
3. Inability to discontinue daily medications other than oral contraceptives or other hormonal therapy.
4. Receipt of an immunoglobulin or blood product within 90 days prior to Study Day 1
5. Any receipt of adalimumab, or other licensed monoclonal antibody
6. Any receipt of another investigational product within 4 weeks or 4 half-lives whichever is longer prior to Study Day 1
7. Abnormal laboratory values per local laboratory parameters from blood collected at screening prior to Study Day 1 randomization as follows:

   * Severe anemia, defined as haemoglobin \<100 g/L or hematocrit \<0.3 L/L
   * absolute neutrophil count, below lower limit of normal (LLN)
   * white blood cell count above upper limit of normal (ULN) or below LLN (i.e., must be within normal limits)
   * ALT, AST, alkaline phosphatase (ALP) above ULN with exception that a one of the three values may be permitted up to 10% above ULN.
   * Creatinine above upper limit of normal ,
   * INR, or activated partial thromboplastin time (APTT) above ULN
8. Abnormal screening urinalysis result that is, per the investigator, clinically significant, or a screening urine dipstick result of ≥2+ protein
9. Positive screening urine test for illicit drugs (amphetamines, methamphetamines, barbiturates, benzodiazepine, cocaine, opiates, PCP, MDMA, methadone)
10. History of systemic allergic reactions, to more than one medication.
11. History or evidence of malignancy.
12. Receipt of immunosuppressive medications other than inhaled or topical immunosuppressant drugs such as corticosteroids within 45 days prior to Study Day 1
13. Hepatitis B surface antigen positive, HIV positive, hepatitis C antibody positive
14. Uncontrolled Type 2 Diabetes or Type I diabetes
15. History systemic fungal infection.
16. Shared a residence within the last year with an individual on anti-tuberculosis treatment or with culture or smear positive tuberculosis
17. Previous medical history that may compromise the safety of the subject in the study, including but not limited to: severe impairment of pulmonary function or other pulmonary disease; chronic illness with signs of cardiac or renal failure; suspected progressive neurological disease or poorly controlled epilepsy
18. History or evidence on physical examination of any systemic disease or any acute or chronic illness that, in the opinion of the investigator, may interfere with the evaluation of the safety of the Study Drug
19. History or evidence of tuberculosis infection
20. Positive Quantiferon test
21. Chest X ray with evidence of malignancy or chronic infection (such as tuberculosis or other)
22. Any current medical, psychiatric, occupational, or substance abuse problem such as alcoholism that, in the opinion of the investigator, will make it unlikely that the subject will comply with the protocol.
23. Elective surgery that would interfere with participation.
24. Live virus vaccination within 60 days and during the study.
25. Blood donation less than 30 days prior to Study Day 1.

Primary outcomes:
measure: AUC0-last (area under the concentration-time curve from time zero to the last non-zero concentration) and AUC0-inf (area under the concentration-time curve from time zero to infinity)
timeFrame: 85 days
measure: Cmax (maximum observed concentration)
timeFrame: 85 days
measure: Residual area (%AUCextrap) [percent extrapolated area under the curve to infinity calculated as 100*(1- AUC0-last / AUC0-inf)]
timeFrame: 85 days
measure: Tmax (time of observed Cmax)
timeFrame: 85 days
measure: t½ (elimination half-life)
timeFrame: 85 days
measure: λz (elimination rate constant)
timeFrame: 85 days
measure: CL/F (apparent body clearance, calculated as Dose/AUC0-inf)
timeFrame: 85 days
measure: Vz/F [apparent volume of distribution, calculated as Dose/ (λz x AUC0-inf)]
timeFrame: 85 days
Secondary outcomes:
measure: Adverse event incidence of SYN060 compared to adalimumab (Humira®) from North American and European sources
timeFrame: 85 days
measure: anti-SYN060 antibodies
timeFrame: 85 days
measure: anti-adalimumab antibodies
timeFrame: 85 days
Other outcomes:
Locations:
city: Melbourne
country: Australia
facility: Nucleus Network
state: Victoria
Study officials:
affiliation: Nucleus Network, Center for Clinical Studies Study Site
name: Niquita Tugiono, MD
role: PRINCIPAL_INVESTIGATOR
References: